CT-0508 is a newly developed CAR-M therapy that has shown a survival benefit in a preclinical study of HER2-positive solid tumors and is currently being tested in a phase I clinical trial in patients with HER2-positive solid tumors (including GC) that have progressed after anti-HER2 therapy; the disclosure of the efficacy data is highly anticipated (NCT04660929). The gene discussed is ERBB2; the disease is gastric cancer.